Tesamorelin + Ipamorelin Combo
The anti-aging GH axis stack: tesamorelin (full-length GHRH, FDA-approved mechanism) combined with ipamorelin (selective GHS-R1a) for synergistic GH and IGF-1
Buy more, save more
Total Price
$150
For research & laboratory use only. Not for human consumption.
Half-Life
Tesamorelin: ~26-38min; Ipamorelin: ~2h
Administration Route
Subcutaneous injection
Visceral Fat + GH Pulse
Tesamorelin targets abdominal fat; ipamorelin adds clean GH pulse
Body Recomposition
Fat reduction + anabolic signal = simultaneous lean mass addition
Anti-Aging + Metabolic
Combined GH restoration with abdominal fat normalisation
Effect Profile
Combined Efficacy
Synergistic Action
Protocol Coverage
Value
Mechanism of Action
Product FAQs
Stacks Well With
Tesamorelin
FDA-approved GHRH analogue (Egrifta) for HIV-associated visceral fat reduction. The most clinically validated GHRH peptide for abdominal fat mobilisation and
Ipamorelin
Highly selective growth hormone secretagogue with minimal cortisol or prolactin stimulation, offering clean GH pulses for muscle growth, recovery, and body
IGF-1 LR3
Long-acting IGF-1 analogue with 3x longer half-life than native IGF-1, driving satellite cell activation, nitrogen retention, and protein synthesis for maximal
Related Products
Tesamorelin
FDA-approved GHRH analogue (Egrifta) for HIV-associated visceral fat reduction. The most clinically validated GHRH peptide for abdominal fat mobilisation and
Ipamorelin
Highly selective growth hormone secretagogue with minimal cortisol or prolactin stimulation, offering clean GH pulses for muscle growth, recovery, and body
CJC-1295 + Ipamorelin Combo
The gold-standard GH secretagogue combination - CJC-1295 (GHRH receptor) and Ipamorelin (ghrelin receptor) producing synergistic, pulsatile GH release 3-5x